These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19779801)

  • 1. HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A.
    Abe K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
    Arch Virol; 2009; 154(10):1671-7. PubMed ID: 19779801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.
    Yang F; Robotham JM; Nelson HB; Irsigler A; Kenworthy R; Tang H
    J Virol; 2008 Jun; 82(11):5269-78. PubMed ID: 18385230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
    Sheaffer AK; Lee MS; Hernandez D; Chaniewski S; Yu F; Falk P; Friborg J; Zhai G; McPhee F
    Antivir Ther; 2011; 16(5):705-18. PubMed ID: 21817192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diverse effects of cyclosporine on hepatitis C virus strain replication.
    Ishii N; Watashi K; Hishiki T; Goto K; Inoue D; Hijikata M; Wakita T; Kato N; Shimotohno K
    J Virol; 2006 May; 80(9):4510-20. PubMed ID: 16611911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.
    Lu L; Dekhtyar T; Masse S; Pithawalla R; Krishnan P; He W; Ng T; Koev G; Stewart K; Larson D; Bosse T; Wagner R; Pilot-Matias T; Mo H; Molla A
    Antiviral Res; 2007 Oct; 76(1):93-7. PubMed ID: 17561278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.
    Robida JM; Nelson HB; Liu Z; Tang H
    J Virol; 2007 Jun; 81(11):5829-40. PubMed ID: 17376913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro.
    Weng L; Tian X; Gao Y; Watashi K; Shimotohno K; Wakita T; Kohara M; Toyoda T
    Biochim Biophys Acta; 2012 Dec; 1820(12):1886-92. PubMed ID: 22954804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.
    Yang F; Robotham JM; Grise H; Frausto S; Madan V; Zayas M; Bartenschlager R; Robinson M; Greenstein AE; Nag A; Logan TM; Bienkiewicz E; Tang H
    PLoS Pathog; 2010 Sep; 6(9):e1001118. PubMed ID: 20886100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replication of a novel subgenomic HCV genotype 1a replicon expressing a puromycin resistance gene in Huh-7 cells.
    Liang C; Rieder E; Hahm B; Jang SK; Paul A; Wimmer E
    Virology; 2005 Mar; 333(1):41-53. PubMed ID: 15708591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
    Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
    Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
    Namba K; Naka K; Dansako H; Nozaki A; Ikeda M; Shiratori Y; Shimotohno K; Kato N
    Biochem Biophys Res Commun; 2004 Oct; 323(1):299-309. PubMed ID: 15351737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
    Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
    Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A.
    Ciesek S; Steinmann E; Wedemeyer H; Manns MP; Neyts J; Tautz N; Madan V; Bartenschlager R; von Hahn T; Pietschmann T
    Hepatology; 2009 Nov; 50(5):1638-45. PubMed ID: 19821520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between subgenomic replicons of hepatitis C virus genotypes 2a (JFH-1) and 1b (Con1 NK5.1).
    Miyamoto M; Kato T; Date T; Mizokami M; Wakita T
    Intervirology; 2006; 49(1-2):37-43. PubMed ID: 16166787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
    Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
    Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
    Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
    Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.
    Fernandes F; Poole DS; Hoover S; Middleton R; Andrei AC; Gerstner J; Striker R
    Hepatology; 2007 Oct; 46(4):1026-33. PubMed ID: 17600342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting lipid metabolism in the treatment of hepatitis C virus infection.
    Amemiya F; Maekawa S; Itakura Y; Kanayama A; Matsui A; Takano S; Yamaguchi T; Itakura J; Kitamura T; Inoue T; Sakamoto M; Yamauchi K; Okada S; Yamashita A; Sakamoto N; Itoh M; Enomoto N
    J Infect Dis; 2008 Feb; 197(3):361-70. PubMed ID: 18248300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.